Online Course Development Sample Clauses

Online Course Development. 1. A faculty member will receive released time or voluntary overload com- pensation for the approved development of an online course, not previ- ously developed, equivalent to the credit hours of the course. Proposed courses must be submitted in writing for review and pre-approved in writing by the xxxx or designee.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Online Course Development. When an adjunct faculty member develops an online course at the request of the Xxxx, the adjunct faculty member shall be compensated for the development of the class at the rate of $2,500 per course. Adjunct faculty are strongly encouraged to work with staff in the Center for Innovative Instruction (CII) on the development of the online course. Before compensation as described above is paid, the Director of CII (or designee) shall evaluate and approve the online course design. After compensation for the course development has been received, the course shell becomes the property of the College. The course shell includes all material except that which is the intellectual property of the faculty member. The adjunct faculty member agrees that for the first two semesters following course development, if requested by the Xxxx, he/she will teach at least one section of the online class.
Sample 1Sample 2Sample 3
Online Course Development. A. faculty member shall participate with other faculty members in his or her discipline and/or department to create, develop, revise, and implement a course or program.
Sample 1Sample 2
Online Course Development. The Professional Employee must receive prior approval before developing a new online course. The Professional Employee will notify the Vice President of Academic Affairs once the course is completed. At this time the course will be reviewed by someone appointed by the Vice President of Academic Affairs for quality and preparedness, and the Professional Employee will be asked to correct any issues. Once the course is approved, offered, and taught, the Professional Employee will receive a supplemental contract at a rate of $400 per credit hour for the new course design. Each course development will only be paid once, and redesigns will not be compensated. EXHIBIT 9 Salary Schedule Years Bachelors Masters Doctorate 0 $36300.00 $39000.00 $41700.00 1 $36600.00 $39500.00 $42400.00 2 $36900.00 $40000.00 $43100.00 3 $37200.00 $40500.00 $43800.00 4 $37500.00 $41000.00 $44500.00 5 $37800.00 $41500.00 $45200.00 6 $38100.00 $42000.00 $45900.00 7 $38400.00 $42500.00 $46600.00 8 $38700.00 $43000.00 $47300.00 9 $39000.00 $43500.00 $48000.00 10 $39300.00 $44000.00 $48700.00 11 $39600.00 $44500.00 $49400.00 12 $39900.00 $45000.00 $50100.00 13 $40200.00 $45500.00 $50800.00 14 $40500.00 $46000.00 $51500.00 15 $40800.00 $46500.00 $52200.00 16 $41100.00 $47000.00 $52900.00 17 $41400.00 $47500.00 $53600.00 18 $41700.00 $48000.00 $54300.00 19 $42000.00 $48500.00 $55000.00 20 $42300.00 $49000.00 $55700.00 Criteria for placement of New Professional Employee on Salary Schedule Prior relevant teaching or industry experience will be granted when placing a new Professional Employee on the salary schedule. Professional Employees with years in K-12 or non-teaching higher education will be given credit at a rate of 2:1 (every two years of experience equals on year placement on the salary schedule). Industry experience will be granted the same credit of 2:1. Professional Employees with teaching experience in Higher Education from an accredited institution will be given credit at a rate of 1:1 (each year equals one year placement on the salary schedule). Seating Capacity for Overload/Concurrent Courses Single-digit section numbers: on-campus/face to face; 25 unless otherwise stated below Section 100+ numbers/online: 25 student limit per section EN 176 (Composition I) and EN 177 (Composition II): 20 student limit per section AL 104: Certified Nurse Aide (CNA): 10 student limit per section AL 110: Certified Medication Aide (CMA): 6 student limit per section Late Fall: a maximum of 3 sections...
Sample 1
Online Course Development. Online course development during the critical incident period will continue to be compensated according to Article 16.4.a.2 of the WIU/UPI Agreement 2017-2021. Unless compensated, online materials developed during the Critical Incident that later become part of an authorized online course will not prevent a faculty member from receiving benefits outlined in Article 16.4.a.2 of the WIU/UPI Agreement 2017-2021.
Sample 1
Online Course Development. Concordia University shall be responsible for developing and providing the Concordia University Materials for the Programs and supporting Instructors in the design and development of the Concordia University Materials. Online courses shall be developed with the quality, features, and functionality that makes them reasonably competitive and comparable with Concordia University’s peer institutions. Greenwood Hall will provide reasonable consultations as needed by Concordia University regarding online course development approaches, new technologies, and methods. At an additional expense and at Concordia University’s sole discretion, Greenwood Hall can also provide Concordia University with instructional design and technical personnel to assist in the development of courses and/or on-going consulting services.
Sample 1
Online Course Development. (a) Upon approval by the appropriate Xxxx, a faculty will receive compensation of $2,000 for the development of an online course that the faculty member has not previously developed. Proposed courses must be submitted in writing for review and pre-approved in writing by the appropriate Xxxx.
Sample 1
AutoNDA by SimpleDocs
Online Course Development. 1.1 The Employee will develop the Course entitled _________________________________________________.
Sample 1

Related to Online Course Development

  • Adverse Developments Promptly after the Lessee acquires knowledge thereof, written notice of:

  • Clinical Development Licensee will have sole responsibility for and sole decision making over the clinical development of any Product arising from the Research Program in the Field. Notwithstanding the foregoing, if Licensee wishes to conduct clinical development of a Development Candidate at Penn and Penn has the clinical expertise, interest and ability to run such a trial as assessed at Penn’s sole discretion, such a study will be conducted under a separate Clinical Trial Agreement to be negotiated by the Parties prior to initiation of such study. Such separate clinical trial agreement will include a detailed clinical development plan, including costs and time lines for conducting the Clinical Trial.

  • Product Development Attach all requested documentation and attach additional pages as necessary. For all requirements include efforts of all Sublicensees. If not applicable, please so indicate by N/A.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Research and Development (i) Advice and assistance in relation to research and development of Party B;

  • Development 3.3 Within twenty (20) Working Days after the Commencement Date and in accordance with paragraphs 3.10 to 3.12 (Amendment and Revision), the Contractor will prepare and deliver to the Authority for approval the full and final Security Plan which will be based on the draft Security Plan set out in Appendix B.

  • New Developments All ideas, inventions, discoveries, concepts, trade secrets, trademarks, service marks or other developments or improvements, whether patentable or not, conceived by Employee, alone or with others, at any time during the term of Employee’s employment, whether or not during working hours or on Employer’s premises, which are within the scope of or related to the business operations of Employer or its Affiliates (“New Developments”), shall be and remain the exclusive property of Employer. Employee agrees that any New Developments which, within one year after the cessation of employment with Employer, are made, disclosed, reduced to a tangible or written form or description or are reduced to practice by Employee and which are based upon, utilize or incorporate Information shall, as between Employee and Employer, be presumed to have been made during Employee’s employment by Employer. Employee further agrees that Employee will not, during the term of Employee’s employment with Employer, improperly use or disclose any proprietary information or trade secrets of any former employer or other person or entity and that Employee will not bring onto Employer premises any unpublished document or proprietary information belonging to any such employer, person or entity unless consented to in writing by such employer, person or entity. At all times during the term of this Agreement and thereafter, Employee shall do all things reasonably necessary to ensure ownership of such New Developments by Employer, including the execution of documents assigning and transferring to Employer all of Employee’s rights, title and interest in and to such New Developments and the execution of all documents required to enable Employer to file and obtain patents, trademarks, service marks and copyrights in the United States and foreign countries on any of such New Developments.

  • Joint Development If joint development is involved, the Recipient agrees to follow the latest edition of FTA Circular 7050.1, “Federal Transit Administration Guidance on Joint Development.”

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

Time is Money Join Law Insider Premium to draft better contracts faster.